We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
- Authors
Hesketh, Paul J; Grunberg, Steven M; Gralla, Richard J; Warr, David G; Roila, Fausto; de Wit, Ronald; Chawla, Sant P; Carides, Alexandra D; Ianus, Juliana; Elmer, Mary E; Evans, Judith K; Beck, Klaus; Reines, Scott; Horgan, Kevin J; Aprepitant Protocol 052 Study Group
- Abstract
In early clinical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic regimen consisting of a type-three 5-hydroxytryptamine antagonist and a corticosteroid. This multicenter, randomized, double-blind, placebo-controlled phase III study was performed to establish definitively the superiority of the aprepitant regimen versus standard therapy in the prevention of chemotherapy-induced nausea and vomiting (CINV).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Vol 21, Issue 22, p4112
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2003.01.095